It has been shown that strong SE‐CRC activity in certain types of cancer leads to “transcriptional addiction” and renders the cancer cells vulnerable to transcription‐targeted therapeutic strategies such as CDK7 inhibition.[24, 25, 26] Transcription inhibition preferentially suppresses the expression of master TFs and SE‐CRC activity, presenting a promising strategy to overcome key challenges of conventional drug therapies, including the lack of druggable targets and the emergence of drug resistance. This evidence concerns the gene CDK7 and colorectal carcinoma.